Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. News about CMPX often centers on its antibody pipeline, clinical trial progress, financing activities, and corporate developments, reflecting its focus on angiogenesis, immune modulation, and tumor growth.
Investors and observers following Compass Therapeutics news can expect regular updates on key product candidates such as tovecimig, CTX-8371, CTX-10726, and CTX-471. The company issues press releases on milestones in the COMPANION-002 Phase 2/3 study of tovecimig in advanced biliary tract cancer, monotherapy data in metastatic colorectal cancer, and cohort expansions or new responses in the Phase 1 study of CTX-8371 in indications like non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma. Preclinical data releases for CTX-10726, including presentations at scientific meetings, also feature prominently.
Compass Therapeutics news coverage additionally includes quarterly financial results, cash and marketable securities updates, and descriptions of anticipated cash runway, as disclosed in earnings press releases and related Form 8-K filings. The company also announces public offerings of common stock and pre-funded warrants, with details on intended use of proceeds for research, clinical development, and preparations for potential commercialization.
Another recurring theme in CMPX news is participation in healthcare and biopharma investor conferences, where Compass presents its pipeline and corporate strategy. Press releases list appearances at events hosted by firms such as J.P. Morgan, Piper Sandler, Evercore, Guggenheim, Stifel, Cantor, and others. Leadership appointments, including additions to the senior management team, are also communicated through Globe Newswire releases.
This news page aggregates these company-issued updates and related coverage, offering a centralized view of clinical, scientific, financial, and corporate developments for Compass Therapeutics and its CMPX stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced promising data from a Phase 2 study of CTX-009 combined with paclitaxel for biliary tract cancers (BTC). The study revealed a 37.5% overall response rate (ORR) across all 24 patients, with a notable 63.6% ORR in the second-line subgroup. Median progression-free survival (PFS) was 9.4 months and overall survival (OS) was 12.5 months. Safety profiles were consistent with prior studies, as 95.8% of patients experienced grade 3 or higher treatment-emergent adverse events. A randomized Phase 2/3 trial of CTX-009 in the U.S. has been initiated, potentially supporting a biologics license application in 2024.
Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced the dosing of the first patient in a Phase 2 clinical study of CTX-009 for metastatic colorectal cancer. This study targets patients who have undergone at least two previous therapies and will evaluate safety and clinical response. The drug is designed to block critical cancer pathways, with prior Phase 1 studies showing confirmed responses. Preliminary results are expected mid-2023, marking a significant development in treatment options for patients facing limited therapies.
Compass Therapeutics, Inc. (CMPX) announced updated Phase 2 study results for CTX-009 combined with paclitaxel in biliary tract cancer (BTC) to be presented at the 2023 ASCO GI Symposium in San Francisco, January 19-21. The event will also showcase ongoing studies including a Phase 2/3 trial for BTC and a Phase 2 trial for metastatic colorectal cancer (CRC).
The presentations aim to highlight the therapeutic potential of CTX-009, which targets DLL4 and VEGF A, and its impact on patient outcomes.
Compass Therapeutics (Nasdaq: CMPX) announced the first patient dosed in a Phase 1b study of CTX-471 combined with KEYTRUDA® for treating advanced solid tumors, including lung and head & neck cancers.
The study aims to evaluate CTX-471's ability to restore responses after checkpoint inhibitor therapy. Previous monotherapy results showed signs of activity.
CTX-471 is a CD137 agonist that activates key immune cells. Four partial responses were observed in earlier trials as of September 30, 2022.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on cancer treatment, will participate in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York City. The company's presentation is scheduled for December 1, 2022, at 8:50 AM ET. A webcast link will be available on their website, and the corporate presentation will be archived for 90 days. Compass Therapeutics is dedicated to developing antibody-based therapies targeting key biological pathways to enhance anti-tumor responses.
Compass Therapeutics (CMPX) announced financial results for Q3 2022, reporting a net loss of $12 million, or $0.12 per share, compared to $6 million, or $0.10 per share, in Q3 2021. Cash and marketable securities were $120.6 million, down from $144.5 million at the end of 2021. The company raised approximately $80 million through a PIPE financing to extend its cash runway into 2026. Key clinical trials for CTX-009 and CTX-471 are underway, with patient enrollment expected to start in Q4 2022. R&D expenses surged by 210% year-over-year, reflecting increased development activities.
BOSTON, Nov. 08, 2022 - Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in two key investor conferences this November. The Stifel Healthcare Conference in New York City is scheduled for November 15, 2022, from 4:10-4:40 PM ET. The Jefferies Global Healthcare Conference in London will take place on November 16, 2022, from 3:15-3:45 PM GMT. Both presentations will be available via webcast, with a replay accessible for 90 days. Compass Therapeutics focuses on developing antibody-based therapies targeting cancer.
Compass Therapeutics, Inc. (CMPX) announced a private investment in public equity (PIPE) financing, selling 25 million shares at $3.21 each, totaling approximately $80 million. The financing, led by Enavate Sciences and other institutional investors, is expected to close by November 8, 2022. Funds will advance their clinical pipeline, including CTX-009, CTX-471, and CTX-8371, extending the company's cash runway into 2026. The securities have not been registered under the Securities Act but will be subject to a registration rights agreement for resale.
Compass Therapeutics (Nasdaq: CMPX) announced a clinical trial collaboration with Merck to evaluate its monoclonal antibody CTX-471 in combination with KEYTRUDA® for treating advanced cancers post anti-PD-1 therapy. The Phase 1b trial will enroll patients with various cancer types and assess safety, pharmacokinetics, and clinical activity. Initial results from earlier trials showed partial responses in patients. This collaboration marks a significant advancement in cancer immunotherapy.
Compass Therapeutics (Nasdaq: CMPX) announced its participation in the 24th Annual H.C. Wainwright Global Investment Conference in New York City, scheduled for September 12 – 14, 2022. The company's presentation is set for September 13, 2022, at 2:30 PM EDT. A webcast of the presentation will be available and archived on their Events page for 90 days.